New factor Xa inhibitor shows promise

Green Cross Corp. said Wednesday it has received approval from the U.S. Food and Drug Administration to conduct Phase 1 clinical trial of a novel anti-thrombotic which can be classified orally or parenterally administered.

The company said the approval comes after successful completion of pre-clinical studies on GCC4401C, one of factor Xa inhibitors.

Currently available anticoagulants ar...